We assessed trends in HCC survival in patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection in New South Wales, Australia. Data on HBV (n 5 54,399) and HCV (n 5 96,908) notifications (1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012) (1) Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the major causes of HCC, (2) responsible for around 80% of cases.
H epatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. (1) Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the major causes of HCC, (2) responsible for around 80% of cases. (3) HCC has a very poor prognosis, (4) given the limited treatment options, with only a minority of patients being eligible for potentially curative strategies. (2, 4) Factors associated with HCC survival include HCC stage, (5, 6) degree of liver function impairment, early HBV/HCV diagnosis and treatment, (7) HCC management received, and the presence of other clinical conditions at time of HCC diagnosis. (2, 8) The past decade has witnessed improvements in HCC management and treatment of HCV and HBV. (9) The impact of these clinical management changes on HCC survival at the population level is unclear.
The mandatory notification of HBV and HCV diagnoses in Australia since 1991 and well-established HCC surveillance systems through the New South Wales (NSW) Cancer Registry and the Admitted Patient Data Collection Database provide the opportunity to evaluate HCC survival at the population level. (10) The aims of this study were (1) to assess trends in HBV-HCC and HCV-HCC survival, including in those who received potentially curative HCC procedures, and (2) to identify factors associated with mortality risk.
Patients and Methods

STUDY POPULATION AND DATA SOURCES
The study population included all persons with HBV or HCV infection with first HCC hospitalization from July 1, 2000. HBV or HCV infection was based on notifications to the Notifiable Conditions Information Management System between January 1, 1993, and December 31, 2012 . Under the Public Health Act 1991 all new HBV and HCV cases are notifiable to the NSW Department of Health. (10) A notifiable HBV case requires detection of HBV surface antigen or HBV DNA. A notifiable HCV case requires detection of anti-HCV antibody or HCV RNA. Personal identifiers were first recorded in the Notifiable Conditions Information Management System in 1992. HBV and HCV notifications were linked to administrative databases to assess potential factors associated with survival following HCC.
HCC ASCERTAINMENT AND CASE DEFINITION
A case of HCC was defined by hospitalization with an HCC code (C22.0) as principal or additional diagnosis. Hospital admissions were obtained from the NSW Admitted Patient Data Collection Database, which includes inpatient hospitalizations from all public and private hospitals in NSW between July 1, 2000, and June 30, 2014. Data on each hospitalization are recorded at separation and include demographic and administrative data as well as the principle and any additional diagnoses coded according to the International Classification of Diseases, Tenth Revision, Australian Modification (ICD-10-AM). The validity of ascertainment of HCC cases through hospitalizationbased codes was assessed by linkage to the NSW Cancer Registry, with data available for the period between January 1, 1994, and December 31, 2009.
Potentially curative HCC procedures were defined as ever receiving liver surgical resection (ICD-10-AM block 953; 30414-00 to 30421-00), liver transplantation (ICD-10-AM block 954; 90317-00), or radiofrequency ablation (RFA; ICD-10-AM block 95650950-00) during or following first HCC hospitalization as principle or additional procedure. Data for these variables were available through the hospitalization data sets for the entire study period (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) .
HBV AND HCV TREATMENT
Overall estimates of HBV and HCV treatment dispensed over the study period were extracted from the Pharmaceutical Benefits Scheme (http://www.pbs.gov. au) and the Kirby Institute annual surveillance reports between 2003 and 2014. (11) Data on estimates of HBV treatment dispensed between 2003 and 2014 were available for entecavir, tenofovir, lamivudine, adefovir dipivoxil, interferon-alfa-2b, interferon-alfa-2a, peginterferon alfa-2a, and telbivudine. Data on estimates of HCV treatment dispensed between 2002 and 2014 were available for interferon 1 ribavirin, pegylated interferon, and pegylated interferon 1 ribavirin.
OTHER DATA SOURCES AND DEFINITIONS
Data on human immunodeficiency virus (HIV) were obtained from the National HIV Registry that includes all individuals notified with HIV between January 1, 1993, and December 31, 2013. Data on deaths among those with HBV or HCV notification was obtained from the NSW Registry for Births, Deaths and Marriages between January 1, 1993, and June 18, 2014. HCV and HBV monoinfections were defined according to the earliest notification record available. HBV/HCV coinfections were defined according to date of notification of the latest infection and included in the HCV cohort.
Alcohol-related hospitalization was defined according to hospitalization with any of the following principal or additional ICD-10 codes: alcohol abuse counseling and surveillance (Z71.4), alcoholic cardiomyopathy (I42.6), alcohol-induced pseudo-Cushing's syndrome (E24.4), alcoholic myopathy (G72.1), alcoholic polyneuropathy (G62.1), alcohol rehabilitation (Z50.2), degeneration of nervous system due to alcohol (G31.2), or mental and behavioral disorders due to alcohol (F10). For HCC and alcohol dependency diagnoses, the first hospitalization as principle or additional diagnosis was used. All diseases listed in the Charlson Comorbidity Index as principle or additional diagnosis were analyzed, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, dementia, pulmonary disease, connective tissue disorder, peptic ulcer, liver disease, diabetes mellitus, diabetes mellitus complications, paraplegia, renal disease, cancers, metastatic cancers, and severe liver disease. (12) The codes for HIV (B20-24) and malignant liver cancers (C22) were excluded from the Charlson Comorbidity Index to avoid overlapping with the main variables of HIV and HCC that were included separately in the analysis. (13) Time to HCC was calculated from date of HBV or HCV notification to date of first HCC hospitalization and categorized as follows: !2 years, <2 years, and at time of or after HCC. (14) Decompensated cirrhosis was defined as ever hospitalized with ascites (R18.0), bleeding esophageal varices (I85.0, I98.3, and I98.21), chronic hepatic failure (including hepatic encephalopathy; K72.1, K72.9), alcoholic hepatic failure (K70.4), or hepatorenal syndrome (K76.7). Codes for decompensated cirrhosis were removed from the Charlson Comorbidity Index in the multivariate analyses of this subpopulation.
LINKAGE PROCESS
Data linkage was completed in two stages. First, HBV and HCV notifications were linked internally to identify patients with HBV/HCV coinfection. All notifications were then matched to all other data sets using probabilistic record linkage methods based on matching demographic data, using ChoiceMaker software. (10) The second stage involved HBV and HCV notification linkage to HIV notifications using deterministic methods based on a 100% match on name code, sex, and date of birth. Data linkage was done by the Centre for Health Record Linkage. (10) 
STATISTICAL ANALYSIS
Analyses of all-cause survival following HCC hospitalization were undertaken using Cox proportional hazards model. The start date was date of first HCC hospitalization. The end date was date of death or end of follow-up (June 31, 2014), whichever occurred first.
Records with missing date of birth, missing age at notification, or death date before the start of the study date (July 1, 2000) were excluded. HCC records with an HCC diagnosis through the NSW Cancer Registry prior to July 1, 2000, were excluded. Analyses were conducted to calculate median survival and probability of all-cause survival following first HCC hospitalization at 1, 2, and 5 years of follow-up.
The main explanatory variables included study period; updated age; gender; place of residence based on the statistical local area (SLA) at time of HBV or HCV notification, which was further grouped into rural, metropolitan, and outer-metropolitan SLAs; place of birth; HIV; HBV/HCV coinfection; alcoholrelated hospitalization; Charlson Comorbidity Index; time to HCC diagnosis following HBV or HCV notification; and ever receiving HCC curative procedures. For variables that are clinically significant but with P > 0.25 in the univariate analysis, sensitivity analyses were done to assess the impact of their 58 (17) 58 (18) 57 (17) 58 ( (6) 12 (6) 17 (7) 15 ( (6) 10 (5) 13 (5) 18 (7) Asia Pacific 529 (73) 156 (77) 190 (74) 183 (69) Europe 68 (9) 22 (11) 32 (13) 14 (5) Other 21 (3) 2 (1) 10 (4) 9 (3) Missing 66 (9) 15 (7) 12 (5) 39 (15) HIV-positive 8 (1) 2 (1) 4 (2) 2(1) Alcohol-related hospitalization 55 (8) 16 (8) 16 (6) 23 ( 174 (24) 33 (16) 60 (23) 81 (30) 1 242 (34) 67 (33) 92 (36) 83 (31) 2 67 (9) 22 (11) 24 (9) 21 (8 inclusion on the adjusted model. Schoenfeld residuals were used to assess violation of the proportional hazards assumption. Analyses were performed using the Stata v14.0 (StataCorp, College Station, TX) and SAS software version 9.4 (SAS Institute, Cary, NC).
ETHICS APPROVAL
Ethics approval for the study was granted by the NSW Population and Health Services Research Ethics Committee. (Tables 1 and 2 ).
Results
PARTICIPANT CHARACTERISTICS
SURVIVAL FOLLOWING FIRST HCC HOSPITALIZATION
Median survival following first HCC hospitalization improved among HBV-HCC patients, from 0. (Table 3; Supporting Table S1 ; Fig. 1 ).
SURVIVAL FOLLOWING HBV-HCC AND HCV-HCC HOSPITALIZATION IN PATIENTS WHO RECEIVED POTENTIALLY CURATIVE PROCEDURES
In HBV-HCC patients who received potentially curative procedures, 1-year and 2-year survival showed (Table 3 and Fig. 2 ). In HCV-HCC patients who received potentially curative procedures, 1-year and 2-year survival showed minimal improvement in 2010-2014 (90%, 78%) compared to 2000-2004 (82%, 75%) ( Table 3 and Fig. 2 ).
SURVIVAL FOLLOWING HBV-HCC AND HCV-HCC HOSPITALIZATION IN PATIENTS WITH DECOMPENSATED CIRRHOSIS
In HBV-HCC patients with decompensated cirrhosis 
FACTORS ASSOCIATED WITH SURVIVAL FOLLOWING HCC HOSPITALIZATION
In the adjusted Cox proportional hazards analyses, factors associated with improved survival following first HCC hospitalization in HBV-HCC patients were later study period (hazard ratio [HR] 5 0.74; 95% CI, 0.57-0.97; P 5 0.03) and potentially curative procedures (liver resection, liver transplantation, and RFA) (HR 5 0.23; 95% CI, 0.17-0.29; P < 0.001), while male gender (HR 5 1.37; 95% CI, 1.03-1.82; P 5 0.03), HIV coinfection (HR 5 3.06; 95% CI, 1.36-6.88; P < 0.01), and Charlson Comorbidity Index !3 (HR 5 1.81; 95% CI, 1.35-2.40; P < 0.001) were associated with reduced survival (Table 4) .
In adjusted Cox proportional hazards analyses, factors associated with improved survival following first HCC hospitalization in HCV-HCC patients were Asia-Pacific country of birth (HR 5 0.68; 95% CI, 0.55-0.84; P < 0.001) and potentially curative procedures (HR 5 0.21; 95% CI, 0.17-0.25; P < 0.001), while age (HR 5 1.01; 95% CI, 1.01-1.02; P < 0.01), rural place of residence (HR 5 1.46; 95% CI, 1.22-1.74; P < 0.001), and HIV coinfection (HR 5 2.71; 95% CI, 1.19-6.15; P 5 0.01) were associated with reduced survival (Table 5) .
In a separate adjusted Cox proportional hazard analysis, combining HBV-HCC and HCV-HCC cohorts stratified by study period, survival was associated with HBV in the later study period (Table 1) .
VALIDATION OF HOSPITALIZATION-BASED HCC DIAGNOSIS AND SURVIVAL ESTIMATES
Use of hospitalization coding data for diagnosis of HCC among people with HBV and HCV was based on its availability through 2014. In contrast, data on HCC cases recorded in the NSW Cancer Registry (22) (23) (24) ; however, survival was not analyzed based on HCC etiology. Recent clinicbased cohorts have also shown improved survival in HBV-HCC compared to HCV-HCC, (4, 25, 26) with an estimated 5-fold increase in median survival in HBV-HCC patients following antiviral therapy (80 months) compared to untreated patients (16 months). (27) A study from Germany reported improved overall survival in HBV-HCC (from 11.0 to 18.6 months) compared to HCV-HCC (from 17.7 to 18.5 months) in patients diagnosed between 1998 and 2009. (4) The advent of interferon-free direct-acting antiviral (DAA) therapy provides considerable optimism that high cure rates will translate into both individual-level and population-level liver disease burden reductions. Reduced HCV-related liver disease progression through DAA-based cure should clearly impact on HCC risk, but the potential impact of DAA treatment on survival following HCV-HCC is unknown. (28, 29) We have hypothesized that improved HBV-HCC survival in our study is related to the introduction of highly effective HBV antiviral therapy from 2006 and resultant reduction in risk of HCC recurrence and hepatic decompensation. In contrast, preliminary evidence suggests that DAA therapy may not have a similar effect on HCC recurrence, with even a suggestion that risk could be increased. (28) There are contrasting views and evidence on HCC risk in the DAA era, (28, 29) but this is clearly a crucial area for ongoing clinical and epidemiological research.
The study has several limitations that need to be considered. First, we have relied on hospitalizationcoded HCC events due to the longer period of available data (2000-2014 versus 2000-2009 in the NSW Cancer Registry). As mentioned, high correlation and short duration between first hospitalization-coded and Cancer Registry HCC diagnoses provide reassurance. Second, the absence of information on liver disease stage is a limitation. Further, the incomplete data on HCC stage at diagnosis led to the exclusion of this variable from the time-to-event analyses. We therefore used hospitalization-coded information on potentially curative procedures (liver resection, liver transplantation, and RFA) to evaluate the impact of earlier-stage HCC diagnosis. These data may be somewhat incomplete as RFA is often administered as a day-only procedure (not recorded in the hospitalization data set). Individual data on HBV antiviral therapy would have been useful to evaluate more directly the impact of improved HBV clinical management. Uptake of HBV antiviral therapy has increased markedly in Australia over the last decade, with the estimated number of people dispensed HBV antiviral drugs increasing from about 2,095 in the first quarter of 2003 to more than 38,015 in the last quarter of 2014, (30) with the assumption that this would also be the case within the HBV-HCC subpopulation. Finally, our population-based estimates of HCC incidence might appear low compared to other studies. (31) However, antiviral HBV therapy would have reduced HBV-HCC risk, and our HCV study population included individuals without chronic HCV (as diagnosis and notification are generally based on anti-HCV antibody detection).
Our findings highlight the generally poor survival following HBV-HCC and HCV-HCC but indicated that enhanced HCC screening, earlier HCC diagnosis, and access to highly effective antiviral therapy could provide considerable population-level improvements in survival. Broad access to HBV and HCV antiviral therapy has the potential to prevent HCC development; therefore, reductions in HCC incidence and improvements in HCC survival should lead to a turnaround in the escalating burden of HCC and related mortality.
